Phase I Study of Q702, an Oral Immunomodulatory Drug, for Treating Blood Cancers and Related Diseases

What this Trial Is About

Researchers are evaluating Q702, an immunomodulatory drug, in a phase I clinical trial for patients with various hematologic malignancies, including relapsed or refractory lymphomas and histiocytic disorders. The study aims to find the best safe dose of Q702, assess its safety and side effects, and explore its impact on patients quality of life and tumor markers. This research is sponsored by Mayo Clinic and focuses on improving treatment options for patients who have limited or failed previous therapies. Participants receive Q702 by mouth daily on days 1-7 and 15-21 of each 28-day cycle. After six cycles, those who have not experienced disease progression may continue treatment for up to six additional cycles based on medical and patient choice. Throughout the study, patients undergo blood and urine tests, imaging scans like PET, CT, or MRI, and bone marrow biopsies to monitor disease and treatment effects. The trial includes a dose-escalation phase followed by an expansion phase to assess overall response. During participation, patients are regularly evaluated with laboratory tests and imaging to track disease status and safety. Quality of life is assessed using patient-reported questionnaires. After completing treatment, participants are followed every six months for two years to monitor long-term outcomes. The main study measures include dose-related toxicities and overall response rate, as well as progression-free and overall survival over up to three years.

Q702 for the Treatment of Patients With Hematologic Malignancies